Karyopharm Therapeutics Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Karyopharm Therapeutics stock has a consensus rating of "Buy" and an average price target of $7.25. The average 1-year stock price forecast is 262.50% higher than the current stock price, while the lowest is $3.00 (+50.00%) and the highest is $11 (+450.00%).

Price Target: $7.25 (+262.50%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$3.00	$7.25	$7.50	$11
Change	+50.00%	+262.50%	+275.00%	+450.00%

Analyst Ratings

The average analyst rating for Karyopharm Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	4	4	4	4	2	2
Buy	2	2	2	2	2	2
Hold	1	1	1	1	2	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	6	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $8	Buy	Maintains	$8	+300.00%	Aug 13, 2026
Maury Raycroft Jefferies	Jefferies	Buy Maintains $14 → $11	Buy	Maintains	$14 → $11	+450.00%	Jul 31, 2026
Colleen M. Kusy Robert W. Baird	Robert W. Baird	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	Jul 31, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Maintains $16 → $7	Buy	Maintains	$16 → $7	+250.00%	Jul 31, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Hold Downgrades $13 → $3	Hold	Downgrades	$13 → $3	+50.00%	Jul 31, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

135.90M

from 146.07M

-6.96%

from 146.07M

Revenue Next Year

177.15M

from 135.90M

30.36%

from 135.90M

EPS This Year

-5.85

from -12.22

EPS Next Year

-2.82

from -5.85

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	209.82M	157.07M	146.03M	145.24M	146.07M	135.90M
Revenue Growth	94.12%	-25.14%	-7.03%	-0.55%	0.57%	-6.96%
Operating Income	-98.27M	-142.20M	-129.54M	-119.44M	-90.71M	-98.75M
Net Income	-124.09M	-165.29M	-143.10M	-76.42M	-196.04M	-160.17M
EPS	-	-	-	-	-12.22	-5.85
Free Cash Flow	-58.64M	-101.35M	-39.95M	-77.09M	-49.43M	143.10M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	137.7M
Avg	135.9M
Low	130.9M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-5.7%
Avg	-7.0%
Low	-10.4%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-5.68
Avg	-5.85
Low	-6.01

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-